Profil bibliographique

Gudrun Schreiber

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

46Publications signalées

1363Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Neurogenetic and Muscular Disorders ResearchMuscle Physiology and DisordersCardiomyopathy and Myosin StudiesConnective tissue disorders researchRNA modifications and cancer

Publications récentes

Accès ouvert 2026 articleOpenAlex

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland – part II – expert based recommendations for surveillance and management of side-effects

Andreas Ziegler, Claudia Weiß, Katharina Vill, Matthias Baumann et autres

0 citationsJournal of Neuromuscular Diseases

Accès ouvert 2026 reviewOpenAlex

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland-part I-systematic literature review and existing evidence

Claudia Weiß, Katharina Vill, Matthias Baumann, Günther Bernert et autres

0 citationsZurich Open Repository and Archive (University of Zurich)

Accès ouvert 2026 preprintOpenAlex

Real-World Outcomes of Risdiplam in 5q Spinal Muscular Atrophy Over 30 Months in Adolescents and Adults: A Multicentre, Prospective, Observational SMArtCARE Study

Maggie C. Walter, M. Weiler, Otgonzul von Velsen, Anika Hüsing et autres

0 citationsSSRN Electronic Journal

Accès ouvert 2025 articleOpenAlex

Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry

Cornelia Voigt-Müller, Michelle Pfaffenlehner, Günther Bernert, Hakan Çetin et autres

2 citationsBrain

Accès ouvert 2025 reviewOpenAlex

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland—part I—systematic literature review and existing evidence

Claudia Weiß, Katharina Vill, Matthias Baumann, Günther Bernert et autres

4 citationsJournal of Neuromuscular Diseases

Accès ouvert 2024 articleOpenAlex

Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial

Oliver Schwartz, Katharina Vill, Michelle Pfaffenlehner, Max Behrens et autres

2 citationsObstetrical & Gynecological Survey

Accès ouvert 2024 articleOpenAlex

Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study

Claudia Weiß, Lena‐Luise Becker, Johannes Friese, Astrid Blaschek et autres

31 citationsThe Lancet Regional Health - Europe

Accès ouvert 2024 articleOpenAlex

Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy

Oliver Schwartz, Katharina Vill, Michelle Pfaffenlehner, Max Behrens et autres

70 citationsArchives of Pediatrics and Adolescent Medicine

Accès ouvert 2024 articleOpenAlex

5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2

Katharina Vill, Moritz Tacke, Anna König, Matthias Baumann et autres

20 citationsJournal of Neurology

Accès ouvert 2023 articleOpenAlex

Real-World Data on the Efficacy of Gene Replacement Therapy for Spinal Muscular Atrophy (SMA)

Lena‐Luise Becker, Johannes Friese, Astrid Blaschek, Andreas Hahn et autres

0 citationsNeuropediatrics

Accès ouvert 2023 articleOpenAlex

Ablation of collagen XII disturbs joint extracellular matrix organization and causes patellar subluxation

Mengjie Zhu, Fabian Metzen, Mark Hopkinson, Janina Betz et autres

8 citationsiScience

Accès ouvert 2023 articleOpenAlex

Early Development of Spinal Deformities in Children Severely Affected with Spinal Muscular Atrophy after Gene Therapy with Onasemnogene Abeparvovec—Preliminary Results

Venla Soini, Gudrun Schreiber, Bernd Wilken, Anna K. Hell

19 citationsChildren

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.